Global

The time is ripe to double down on local “market-fit” capabilities.

US pharma industry handcuffed by restrictions, group argues.

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.

An ecosystem perspective is the first step.

Member states air concerns over excess supplies of COVID vaccines.

Making sense of surprise rejection of draft proposals.

Commercial Health Insurance may bring more opportunities for market access in China.

Global go-to-market strategies in region require a revamped gameplan.

Patient safety and data protection concerns highlight hesitancy.

The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.

The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.

And, in equal measure, patients and doctors—as EU mulls new rules.

Proposed SoHO reform elicits wide support, but risks acknowledged.

Jimenez discusses bringing care to diverse and underserved communities.

Industry leaders discuss new technologies, research, and investment strategies.

Continent has shed its ‘emerging’ status on world biopharma stage.

Legislative-reform alliance makes for strange bedfellows.

Group’s ideas to change EU pricing rules draw captive audience.

Investments setting up sector for future success that could one day rival its US counterpart.

Kalidas spoke with Pharm Exec about her efforts to bring equity to underserved patients and their communities through Bayer’s Oncology Sustainability Initiative.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Recent growth in pharma makes Ireland an ideal candidate for expansion opportunities.

The risky business of outmaneuvering Europe’s drug pricing authorities.